Creo Medical - Second robotics deal signed
Creo Medical has announced the signing of a non-exclusive licence and royalty agreement with a global surgical robotics company, CMR Surgical, providing further momentum to an already busy FY22. Under the terms of the agreement, CMR will be permitted to integrate certain features of Creo’s Kamaptive technology into its Versius surgical robotic system, a next-generation laparoscopic surgery robot. The details of the licence and royalty agreement remain undisclosed, but the deal represents another win for the company’s ‘Powered by Kamaptive’ licensing programme after a collaboration with Intuitive Surgical was announced in May 2022. We view the new agreement as strengthening Creo’s offering in the surgical robotics sector and believe it could hold upside potential if development is successful. When specifics of the agreement are made public, we will revisit our valuation.Creo Medical Group is a medical device company focused on the field of surgical endoscopy, a recent development in minimally invasive surgery. Co. is focused on developing and commercializing a suite of medical devices based on its CROMA electrosurgery platform.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.